These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32123158)

  • 21. Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma.
    Bal S; Landau HJ; Shah GL; Scordo M; Dahi P; Lahoud OB; Hassoun H; Hultcrantz M; Korde N; Lendvai N; Lesokhin AM; Mailankody S; Shah UA; Smith E; Devlin SM; Avecilla S; Dogan A; Roshal M; Landgren O; Giralt SA; Chung DJ
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):1394-1401. PubMed ID: 32442725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone.
    Yoroidaka T; Yamashita T; Murata R; Yoshihara K; Yoshihara S; Ueda M; Nakao S; Matsue K; Takamatsu H
    Anticancer Res; 2023 Jan; 43(1):157-165. PubMed ID: 36585165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies.
    Landgren O; Kazandjian D; Roussel M; Jasielec J; Dytfeld D; Anderson A; Kervin TA; Iskander K; McFadden I; Jakubowiak AJ
    Leuk Lymphoma; 2022 Oct; 63(10):2413-2421. PubMed ID: 35549810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.
    Kubicki T; Dytfeld D; Wróbel T; Jamroziak K; Robak P; Czyż J; Tyczyńska A; Druzd-Sitek A; Giannopoulos K; Szczepaniak T; Łojko-Dankowska A; Matuszak M; Gil L; Puła B; Rybka J; Majcherek M; Usnarska-Zubkiewicz L; Szukalski Ł; Zaucha JM; Mikulski D; Czabak O; Lahoud OB; Stefka A; Derman BA; Jakubowiak AJ
    Br J Haematol; 2023 Dec; 203(5):792-802. PubMed ID: 37691005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
    Stewart AK; Dimopoulos MA; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel DS; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Buchanan J; Cocks K; Yang X; Xing B; Zojwalla N; Tonda M; Moreau P; Palumbo A
    J Clin Oncol; 2016 Nov; 34(32):3921-3930. PubMed ID: 27601539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
    Steinmetz HT; Singh M; Lebioda A; Gonzalez-McQuire S; Rieth A; Schoehl M; Poenisch W
    Oncol Res Treat; 2020; 43(9):449-459. PubMed ID: 32694243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
    Derman BA; Kansagra A; Zonder J; Stefka AT; Grinblatt DL; Anderson LD; Gurbuxani S; Narula S; Rayani S; Major A; Kin A; Jiang K; Karrison T; Jasielec J; Jakubowiak AJ
    JAMA Oncol; 2022 Sep; 8(9):1278-1286. PubMed ID: 35862034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT.
    Tilmont R; Yakoub-Agha I; Eikema DJ; Zinger N; Haenel M; Schaap N; Arroyo CH; Schuermans C; Besemer B; Engelhardt M; Kuball J; Michieli M; Schub N; Wilson KMO; Bourhis JH; Mateos MV; Rabin N; Jost E; Kröger N; Moraleda JM; Za T; Hayden PJ; Beksac M; Mclornan D; Schönland S; Manier S
    Bone Marrow Transplant; 2023 Nov; 58(11):1182-1188. PubMed ID: 37543712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
    Jakubowiak AJ; Campioni M; Benedict Á; Houisse I; Tichy E; Giannopoulou A; Aggarwal SK; Barber BL; Panjabi S
    J Med Econ; 2016 Nov; 19(11):1061-1074. PubMed ID: 27224006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.
    Manasanch EE; de Larrea CF; Zingone A; Steinberg SM; Kwok M; Tageja N; Bhutani M; Kazandjian D; Roschewski M; Wu P; Carter G; Zuchlinski D; Mulquin M; Lamping L; Costello R; Burton D; Gil LA; Figg WD; Maric I; Calvo KR; Yuan C; Stetler-Stevenson M; Korde N; Landgren O
    Leuk Lymphoma; 2017 Mar; 58(3):639-645. PubMed ID: 27687480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone.
    Kubicki T; Jamroziak K; Robak P; Czyż J; Tyczyńska A; Druzd-Sitek A; Giannopoulos K; Wróbel T; Nowicki A; Szczepaniak T; Łojko-Dankowska A; Matuszak M; Gil L; Puła B; Szukalski Ł; Końska A; Zaucha JM; Walewski J; Mikulski D; Czabak O; Robak T; Kruk-Kwapisz D; Derman BA; Major A; Jakubowiak AJ; Dytfeld D
    Pol Arch Intern Med; 2024 May; 134(5):. PubMed ID: 38747414
    [No Abstract]   [Full Text] [Related]  

  • 32. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
    Dimopoulos MA; Stewart AK; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel D; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak A; San-Miguel J; Ludwig H; Ro S; Aggarwal S; Moreau P; Palumbo A
    Blood Cancer J; 2017 Apr; 7(4):e554. PubMed ID: 28430175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates.
    Terpos E; Kastritis E; Ntanasis-Stathopoulos I; Christoulas D; Papatheodorou A; Eleutherakis-Papaiakovou E; Kanellias N; Fotiou D; Ziogas DC; Migkou M; Roussou M; Trougakos IP; Gavriatopoulou M; Dimopoulos MA
    Am J Hematol; 2019 Apr; 94(4):400-407. PubMed ID: 30592079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma.
    Dytfeld D; Jasielec J; Griffith KA; Lebovic D; Vesole DH; Jagannath S; Al-Zoubi A; Anderson T; Detweiler-Short K; Stockerl-Goldstein K; Ahmed A; Jobkar T; Durecki DE; McDonnell K; Mietzel M; Couriel D; Kaminski M; Vij R; Jakubowiak AJ
    Haematologica; 2014 Sep; 99(9):e162-4. PubMed ID: 24972772
    [No Abstract]   [Full Text] [Related]  

  • 36. Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma.
    Boccon-Gibod C; Talbot A; Le Bras F; Frenzel L; Royer B; Harel S; Lombion N; Belhadj K; Cuccuini W; Arnulf B
    Br J Haematol; 2020 May; 189(3):e73-e76. PubMed ID: 32012229
    [No Abstract]   [Full Text] [Related]  

  • 37. The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future!
    Kazandjian D; Dew A; Hill E
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101150. PubMed ID: 32139015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.
    Kazandjian D; Korde N; Mailankody S; Hill E; Figg WD; Roschewski M; Landgren O
    JAMA Oncol; 2018 Dec; 4(12):1781-1783. PubMed ID: 30477009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma.
    Iqbal SM; Stecklein K; Sarow J; Krabak M; Hillengass J; McCarthy P
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):e33-e36. PubMed ID: 30337238
    [No Abstract]   [Full Text] [Related]  

  • 40. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.